15 Best Biotech Stocks to Buy According to Billionaires

Page 2 of 13

12. Illumina, Inc. (NASDAQ:ILMN

Number of Billionaires: 13 

Dollar Value of Billionaire Holdings: $308,613,702 

Illumina, Inc. (NASDAQ:ILMN), standing twelfth among best biotech stocks to buy according to billionaires, is a leading biotech company specializing in genetic sequencing and analysis. It develops and sells advanced tools for DNA sequencing, serving researchers, healthcare providers, and pharmaceutical companies worldwide. The company stands out as a pioneer in next-generation sequencing (NGS) technology, with its sequencing by synthesis (SBS) method setting the industry standard for accuracy and efficiency, giving it a strong competitive edge.

Illumina, Inc. (NASDAQ:ILMN)’s Q4 2024 financial report reflects resilience and growth potential. The company’s core revenue reached $1.1 billion, marking a 1% increase from Q4 2023, though full-year revenue declined by 2% to $4.3 billion. Despite this, the business improved its operating margins, with GAAP operating margin at 15.8% and non-GAAP at 19.7%.

Looking ahead to 2025, the company expects modest revenue growth in the low single digits. The company also aims to strengthen profitability, targeting a 23% non-GAAP operating margin and projected earnings per share between $4.50 and $4.60.

To drive future growth, the corporation is expanding its technological and scientific collaborations. It has partnered with NVIDIA to enhance multi-omic data analysis and is launching a proteomics pilot program with UK Biobank and biopharma collaborators. Additionally, investments in the Truveta Genome Project and a partnership with Regeneron aim to advance scientific innovation. Illumina, Inc. (NASDAQ:ILMN) is also expanding its NovaSeq X Series and TruSight Oncology solutions to reinforce its market leadership.

Page 2 of 13